- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ODYSSEY THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Di | Oppenheimer initiates Odyssey Therapeutics stock with outperform rating | 1 | Investing.com | ||
| Di | TD Cowen initiates Odyssey Therapeutics stock at Buy on drug pipeline | 1 | Investing.com | ||
| Di | JPMorgan initiates Odyssey Therapeutics stock rating at Overweight | 1 | Investing.com | ||
| 11.05. | Odyssey Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.05. | Odyssey Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 08.05. | Autoimmune diseases biotech Odyssey Therapeutics prices upsized IPO at $18, the high end of the range | 1 | Renaissance Capital | ||
| 08.05. | Odyssey Therapeutics Prices Upsized IPO Of 15.50 Mln Shares At $18/shr | 654 | AFX News | WASHINGTON (dpa-AFX) - Odyssey Therapeutics Inc. announced the pricing of its upsized initial public offering of 15.50 million shares of common stock at $18.00 per share. The company has also... ► Artikel lesen | |
| 08.05. | Odyssey Therapeutics prices $304M IPO at $18 per share | 2 | Investing.com | ||
| 08.05. | Odyssey Therapeutics Inc: Odyssey Therapeutics Announces Pricing of Upsized Initial Public Offering | 183 | GlobeNewswire (Europe) | BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. ("Odyssey"), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune... ► Artikel lesen | |
| 05.05. | Odyssey Therapeutics, Inc. - 8-A12B, Registration of securities | - | SEC Filings | ||
| 04.05. | Autoimmune diseases biotech Odyssey Therapeutics sets terms for $225 million IPO, pricing this week | 1 | Renaissance Capital | ||
| 04.05. | Odyssey Therapeutics, Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 17.04. | Autoimmune diseases biotech Odyssey Therapeutics refiles for a $100 million IPO | 2 | Renaissance Capital | ||
| 17.04. | Odyssey Therapeutics, Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
| 16.03. | Odyssey Therapeutics appoints H Martin Seidel to Scientific Advisory Board | 1 | PMLiVE | ||
| 21.01. | Odyssey Therapeutics Appoints Jolie Siegel EVP and General Counsel | 1 | Contract Pharma | ||
| 10.09.25 | Jeito Capital announces significant participation in oversubscribed $213M Series D financing for Odyssey Therapeutics to advance clinical pipeline addressing autoimmune diseases with high unmet needs | 421 | GlobeNewswire (Europe) | Jeito Capital announces significant participation in oversubscribed $213M Series D financing for Odyssey Therapeutics to advance clinical pipeline addressing autoimmune diseases with high unmet needs
Investment... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,095 | 0,00 % | EQS-NVR: Evotec SE: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Evotec SE
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Evotec SE: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem... ► Artikel lesen | |
| MODERNA | 39,120 | -0,27 % | Neue CAR-T-Erfolge bei Autoimmunerkrankungen: Warum Lösungen für Zelltherapien vor dem nächsten Wachstumsschub stehen könnten | ||
| VALNEVA | 2,380 | -2,22 % | Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy | Original-Research: Valneva SE - von First Berlin Equity Research GmbH
28.05.2026 / 17:08 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 14,060 | 0,00 % | PALATIN TECHNOLOGIES INC - 8-A12B, Registration of securities | ||
| VIVOSIM LABS | 1,290 | 0,00 % | VivoSim Labs, Inc.: VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales | SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,126 | -100,00 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results | Rolling submission of Biologics License Agreement (BLA) to U.S. Food and Drug Administration (FDA) seeking ST-920 approval is in progress. Six sites activated in Phase 1/2 STAND study evaluating ST-503... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 11,240 | -0,53 % | Intellia to present Phase 3 gene editing trial data at congress | ||
| ARBUTUS BIOPHARMA | 3,630 | -1,09 % | Arbutus Biopharma Corp - 8-K, Current Report | ||
| XOMA ROYALTY | 35,600 | -1,11 % | Weekly Buzz: FDA Okays AstraZeneca's Saphnelo Pen, EC Clears Crinetics Pharmaceuticals' Acromegaly Drug, Soligenix Slumps, Ligand Snaps Up XOMA Royalty | BASEL (dpa-AFX) - This week's biotech landscape witnessed regulatory approvals in the US and Europe, acquisitions, and a few trial halts, alongside positive data readouts spanning multiple therapeutic... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 2,750 | 0,00 % | Cellectar Biosciences, Inc.: Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting | Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy Plans to Initiate Phase... ► Artikel lesen | |
| AIM IMMUNOTECH | 0,073 | -100,00 % | AIM ImmunoTech Inc.: AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones | OCALA, Fla., June 01, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced a significant milestone in its pancreatic cancer development program... ► Artikel lesen | |
| NOVOCURE | 13,195 | -4,90 % | Novocure Reports First Quarter 2026 Financial Results | Quarterly net revenues of $174 million, up 12% year-over-year, driven by global growth in Optune Gio
Optune Pax approved by the U.S. FDA and launched for the treatment of locally advanced pancreatic... ► Artikel lesen | |
| PHARMING | 1,054 | -1,45 % | Pharming Group N.V.: Pharming Group to participate in Fireside Chat at 2026 Jefferies Global Healthcare Conference in New York | Leiden, the Netherlands, June 2, 2026: Pharming Group ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced its participation in the 2026 Jefferies Global Healthcare Conference in New... ► Artikel lesen | |
| CYTOKINETICS | 61,68 | +1,15 % | Cytokinetics, Incorporated: Cytokinetics bringt MYQORZO (aficamten) in der Europäischen Union auf den Markt; der erste kommerzielle Vertrieb erfolgt in Deutschland | Auf den erfolgreichen Start in den USA folgt nun die Markteinführung in Europa
SOUTH SAN FRANCISCO, Kalifornien, und ZUG, Schweiz, June 01, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:... ► Artikel lesen | |
| TRAWS PHARMA | 1,440 | +1,41 % | Traws Pharma, Inc.: Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks | Broad-spectrum antiviral agent with potential utility against Hantavirus, Ebola and Lassa Utilizing a novel dual-strike mechanism, the proprietary combination agent has the potential to deliver a... ► Artikel lesen |
ODYSSEY THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 16,930 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ODYSSEY THERAPEUTICS INC finden Sie auf Wallstreet Online.